Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
Abstract
The success of targeted cancer therapy is limited by drug resistance that can result from tumor genetic heterogeneity. The current approach to address resistance typically involves initiating a new treatment after clinical/radiographic disease progression, ultimately resulting in futility in most patients. Towards a potential alternative solution, we developed a novel computational framework that uses human cancer profiling data to systematically identify dynamic, pre-emptive, and sometimes non-intuitive treatment strategies that can better control tumors in real-time. By studying lung adenocarcinoma clinical specimens and preclinical models, our computational analyses revealed that the best anti-cancer strategies addressed existing resistant subpopulations as they emerged dynamically during treatment. In some cases, the best computed treatment strategy used unconventional therapy switching while the bulk tumor was responding, a prediction we confirmed in vitro. The new framework presented here could guide the principled implementation of dynamic molecular monitoring and treatment strategies to improve cancer control.
Additional Information
© 2017 the Author(s). This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Received: 23 November 2016; Accepted: 06 February 2017; Published online: 13 March 2017. The authors acknowledge funding support from NIH, the Pew-Stewart Charitable Trust, the Kinship-Searle Foundation, and the Van Auken Foundation (to TGB). C.M.B. was supported by grants from The Lung Cancer Research Foundation (P0060520/A123243) and AACR (14-40-18-BLAK). J.C.D. provided funding for V.D.J. and N.M. Author Contributions: T.G.B., V.D.J. and C.M.B. conceived and designed the study. V.D.J. conceived and developed the math model and control theoretic algorithm. J.C.D. advised on control theoretic problem approach. V.D.J. and N.M. implemented the algorithm. C.M.B. and V.D.J. designed experiments, performed experiments and analyzed data. V.O., L.L. and E.P. performed experiments. L.L., and B.C.B. performed sequencing. S.A., B.C.B., and B.S.T. analyzed sequencing data. M.A.G. provided tumors for analysis. V.D.J., C.M.B. and T.G.B. wrote the manuscript, with input from all authors. We thank Nikoletta Sidiropoulos for pathology assessment and independent confirmation of the BRAF V600E mutation. We thank Tyrrell Nelson for assistance in sequencing library preparation. We thank Swapna Vemula for assistance with FISH analysis. We thank Russell Johnson for assistance with figure formatting. Competing interests: T.G.B. is a consultant to Astrazeneca, Novartis, Array, Revolution Medicines and has received research funding from Ignyta. C.M.B. has received funding from Clovis Oncology, Ignyta, and MedImmune.Attached Files
Published - srep44206.pdf
Submitted - 086553.full.pdf
Supplemental Material - srep44206-s1.pdf
Files
Additional details
- PMCID
- PMC5347024
- Eprint ID
- 74066
- Resolver ID
- CaltechAUTHORS:20170206-090159752
- NIH
- Pew-Stewart Charitable Trust
- Kinship-Searle Foundation
- Van Auken Foundation
- Lung Cancer Research Foundation
- P0060520/A123243
- American Association for Cancer Research
- 14-40-18-BLAK
- Created
-
2017-02-06Created from EPrint's datestamp field
- Updated
-
2023-06-01Created from EPrint's last_modified field